All In Biotech

Drug Trial Radar · NCT03850574

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Mar 11, 2019

Primary completion

Nov 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Aptose Biosciences Inc.Industry
Sponsor type
Industry
First posted
Feb 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.

Conditions

  • Leukemia, Myeloid, Acute
  • Refractory AML
  • Relapsed Adult AML
  • Myelodysplastic Syndrome With Excess Blasts-2
  • Chronic Myelomonocytic Leukemia

Interventions

  • TuspetinibDrug

    Daily (QD), continuous dosing

  • Venetoclax Oral TabletDrug

    Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets

  • Azacitidine for Intravenous InfusionDrug

    Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of drug-related adverse eventsTime frame: 4 years
  2. Maximum tolerated dose (MTD) of tuspetinibTime frame: 4 years
  3. Maximum plasma concentration (Cmax)Time frame: Cycle 1 (at least 28 days)
  4. Minimum plasma concentration (Cmin)Time frame: Cycle 1 (at least 28 days)
  5. Area under the plasma concentration-time curve (AUC)Time frame: Cycle 1 (at least 28 days)
  6. Time to maximum concentration (Tmax)Time frame: Cycle 1 (at least 28 days)
  7. Terminal half-life (t1/2)Time frame: Cycle 1 (at least 28 days)
  8. Volume of distributionTime frame: Cycle 1 (at least 28 days)
  9. Plasma clearance (CL)Time frame: Cycle 1 (at least 28 days)
  10. Recommended Phase 2 dose (RP2D) of tuspetinibTime frame: 4 years

Locations

34 sites in 6 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Active not recruiting

  • University of California Irvine

    Irvine, California · Recruiting

  • UCSD Moores Cancer Center

    La Jolla, California · Active not recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • University of California, Davis

    Sacramento, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Miami - Miller School of Medicine

    Miami, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Active not recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic - Taussig Cancer Center

    Cleveland, Ohio · Active not recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • MD Anderson Cancer Center

    Huston, Texas · Recruiting

  • Border Medical Oncology

    Albury, New South Wales, Australia · Active not recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Active not recruiting

  • Townsville University Hospital

    Townsville, Queensland, Australia · Active not recruiting

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Active not recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Active not recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Saxony, Germany · Active not recruiting

  • Charité Universitätsmedizin Berlin

    Berlin, State of Berlin, Germany · Active not recruiting

  • Auckland City Hospital

    Grafton, Auckland, New Zealand · Active not recruiting

  • Kyungpook National University Hospital

    Daegu, South Korea · Active not recruiting

  • Pusan National University Hospital

    Pusan, South Korea · Active not recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Active not recruiting

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Completed

  • Asan Medical Center

    Seoul, Seoul, South Korea · Active not recruiting

  • Samsung Medical Center

    Seoul, Seoul, South Korea · Active not recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Barcelona, Spain · Active not recruiting

  • Hospital Quirón Madrid

    Pozuelo de Alarcón, Madrid, Spain · Active not recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, Spain · Active not recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Valencia, Spain · Active not recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, Valencia, Spain · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.